Assessing Quality of Life in Elderly Patients with Low Grade Non-Hodgkin Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the changes in quality of life (QoL) among elderly patients diagnosed with low-grade non-Hodgkin lymphoma during their clinical management. It will involve a prospective, multicenter approach, enrolling 150 patients aged 70 and older who have a confirmed diagnosis of indolent B cell non-Hodgkin lymphoma. Participants will undergo a Comprehensive Geriatric Assessment and will have their QoL assessed at baseline, after treatment, and one year post-therapy. The study seeks to identify key factors influencing QoL throughout the treatment process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Local histological diagnosis of indolent B cell non-Hodgkin lymphoma: follicular lymphoma, marginal zone lymphoma (nodal, MALT (Mucosa-Associated Lymphoid Tissue), splenic), lymphoplasmacytic lymphoma/ Waldenström macroglobulinemia)
* Age ≥ 70 years
* Patient candidates to receive treatment for lymphoma
* Patient previously untreated for lymphoma
* Evaluation of Comprehensive Geriatric Assessment at baseline
* Ability to provide informed consent: subject understands and voluntarily signs an informed consent form approved by an IEC (Independent Ethics Committee), prior to registration into the study

Note: Patient treated in the context of a clinical trial is admitted

Exclusion Criteria:

* none

Where it's running

• S.C. Ematologia - A.O. SS. Antonio e Biagio e Cesare Arrigo
  Alessandria, Alessandria, Italy Recruiting
• Clinica di Ematologia - A.O.U. Ospedali Riuniti
  Ancona, Italy, Italy Recruiting
• U.O.C. Ematologia - IRCCS Istituto Tumori Giovanni Paolo II
  Bari, Italy, Italy Recruiting
• Ematologia - ASST Spedali Civili di Brescia
  Brescia, Italy, Italy Recruiting
• Ematologia - Ospedale di Castelfranco Veneto
  Castelfranco Veneto, Italy, Italy Recruiting
• U.O.C. di Ematologia - Azienda Ospedaliera Universitaria Policlinico - Rodolico S. Marco
  Catania, Italy, Italy Recruiting

Study contacts

• Principal investigator: Salvatrice Mancuso — Ematologia - A.O.U. Policlinico Giaccone, Palermo
• Study coordinator: Marina Cesaretti
• Email: mcesaretti@filinf.it
• Phone: +39 059 9769913

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Epcoritamab plus rituximab as first treatment for follicular lymphoma

  This trial tests whether adding epcoritamab to rituximab is safe and effective as the first treatment for adults with untreated follicular lymphoma.

  Recruiting at 6 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 5 other locations · NCT05783609

• T cell receptor depletion for blood cancer treatment

  This study is testing a new way to treat blood cancers by using a special treatment before a stem cell transplant to see if it helps both kids and adults do better after the procedure.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05735717

• Hematopoietic stem cell transplant for blood cancers

  This study is testing two different ways of doing stem cell transplants for people with blood cancers to see which method works better and is safer.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT03314974

• Epcoritamab treatment for patients with follicular lymphoma not responding to initial therapy

  This study is testing if a new treatment called epcoritamab can help people with follicular lymphoma who didn't respond well to their first therapy.

  Recruiting at 3 sites Phase 2 Beth Israel Deaconess Medical Center · Stanford, California and 2 other locations · NCT06510361

• T-Cell Therapy for Adults with Relapsed B-Cell Non-Hodgkin's Lymphoma

  This study is testing a new T-cell therapy to see if it can help adults with relapsed B-cell non-Hodgkin's lymphoma feel better.

  Recruiting at 5 sites Phase 1/2 Estrella Immunopharma, Inc. · Sacramento, California and 4 other locations · NCT06343311

• Evaluating MT-601 for patients with relapsed or refractory lymphoma

  This study is testing a new treatment called MT-601 to see if it can help people with relapsed or hard-to-treat lymphoma feel better.

  Recruiting at 7 sites Phase 1 Marker Therapeutics, Inc. · Duarte, California and 6 other locations · NCT05798897

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.